Semaglutide results at 4 weeks. - Reddit

Why does semaglutide show limited results at 4 weeks?

Semaglutide for weight management follows a structured dose-escalation schedule. Patients typically start at 0.25 mg once weekly for the first four weeks, then step up to 0.5 mg, and continue increasing every four weeks until reaching the target maintenance dose of 2.4 mg weekly. The full escalation can take 16 to 20 weeks.

At the 0.25 mg starting dose, the medication is primarily being tolerated by the body, not yet delivering its full pharmacological effect. This is by design. Nausea, the most common early side effect, is strongly dose-dependent, and the slow titration schedule significantly reduces its severity and likelihood.

What this means practically: if you are evaluating semaglutide results at 4 weeks and feeling underwhelmed, that is the expected experience for most patients at this stage. The 4-week mark is not a meaningful assessment point for the medication’s full effect on weight.

What do the clinical trials show at early timepoints?

The landmark STEP clinical trial program enrolled thousands of adults and tracked outcomes over 68 weeks. While the trials were not specifically designed to isolate 4-week results, the data from early timepoints paints a consistent picture:

• Appetite changes come first. Many participants reported reduced appetite and decreased food cravings within the first two weeks, even at the starting dose. GLP-1 receptor agonists work partly by slowing gastric emptying and signaling satiety to the brain, effects that begin at any dose level.
• Early weight loss is modest. At four weeks on the starting dose, average weight reduction in trial participants was approximately 2 to 4 lbs (roughly 1 to 2 kg). This is meaningful for some people and hard to detect for others depending on starting weight and measurement variability.
• The curve steepens later. The STEP 1 trial showed the most pronounced weight-loss rate occurring between weeks 8 and 28, as participants moved through higher doses. By week 68, the semaglutide group had achieved a mean weight reduction of approximately 15% of body weight.

What do “results” actually look like at week 4?

The 4-week experience varies considerably by individual. Some common patterns reported by patients and observed in clinical settings:

Reduced food noise

One of the earliest and most frequently described effects of semaglutide is a quieting of the constant mental preoccupation with food. Many patients describe this as “not thinking about food as much” — intrusive thoughts about eating, snacking between meals, or compulsive eating urges become less frequent. This can happen within the first week or two, even at 0.25 mg.

Smaller portion comfort

Semaglutide slows gastric emptying, which prolongs the feeling of fullness after eating. Many early-stage patients notice they feel satisfied with smaller portions without trying. This is the mechanism that underlies long-term caloric reduction, but it begins operating at the starting dose.

Mild GI adjustment

Nausea, constipation, or mild stomach discomfort are the most commonly reported early side effects. These tend to be most prominent in the first one to two weeks after each dose increase and often settle down as the body adapts. The 0.25 mg starting dose specifically exists to minimize these effects before the dose is escalated.

The scale may not reflect what is happening

Early weight changes can be obscured by fluid shifts, digestive timing, and normal day-to-day body weight variation of 2 to 4 lbs. Patients who weigh themselves daily and see fluctuation should understand that the meaningful signal emerges over weeks and months, not days.

Which individual factors influence early results?

Clinical trial data reports averages, and individual experience spans a wide range around that average. Several factors shape how much a person notices at the 4-week mark:

• Starting weight: Patients with higher starting weights may see larger absolute numbers on the scale early on, while percentage-based loss tends to converge over time.
• Dietary changes: Semaglutide reduces appetite but does not eliminate eating behavior. Patients who make meaningful dietary changes alongside the medication typically see more movement early on.
• Insulin sensitivity: People with insulin resistance may experience stronger early appetite effects from GLP-1 receptor agonism because of the compound glucose-insulin signaling dynamics involved.
• GI sensitivity: Patients with more sensitive GI systems may require longer at the starting dose before titrating, which can extend the timeline before reaching therapeutic doses.

When do semaglutide results become more pronounced?

Based on trial data, the periods when most patients report the most noticeable changes are:

• Weeks 8–16: As doses escalate to 0.5 mg and then 1.0 mg, appetite suppression becomes more consistent and measurable weight change accelerates for most patients.
• Weeks 16–28: Higher doses (1.7 mg and 2.4 mg) represent the full therapeutic range. This is where the STEP trial weight loss curves show their steepest decline.
• Months 3–6: A useful benchmark for assessing whether the protocol is working well for a given patient. Clinicians often use this window to evaluate dose optimization.

For context: in the STEP 1 trial, participants on 2.4 mg semaglutide lost a mean of approximately 15% of body weight over 68 weeks. That figure is an average across a large population — some patients lost more, some less. The 4-week mark represents less than 6% of the total trial duration.

Compounded semaglutide: the same molecule, different access pathway

Compounded semaglutide is prepared by licensed 503A compounding pharmacies in the United States and prescribed by licensed clinicians. It is not an FDA-approved drug — no compounded medication is. Patients using compounded semaglutide follow the same dose-escalation schedule and the same physiological timeline described above.

PepScribe connects patients with licensed clinicians who review individual health history before recommending a protocol. Compounded semaglutide is prepared in the USA by licensed 503A pharmacies. No hidden overseas supply chain.

If you are considering semaglutide for weight management, a clinician review is the appropriate starting point — not to evaluate 4-week results, but to determine whether the protocol is right for your baseline health profile.

Frequently asked questions